SLC25A26-mediated SAM compartmentalization coordinates translation and bioenergetics during cardiac hypertrophy

Ningning Guo; Jian Lv; Yu Fang; Qiuxiao Guo; Jiajie Li; Junmei Wang; Xiao Ma; Qingqing Yan; Fuqing Jiang; Shuiyun Wang; Li Wang; Zhihua Wang

doi:10.1101/2024.07.30.24311193

ABSTRACT

BACKGROUND The heart undergoes hypertrophy as a compensatory mechanism to cope with increased hemodynamic stress, and it can transition into a primary driver of heart failure. Pathological cardiac hypertrophy is characterized by excess protein synthesis. Protein translation is an energy-intensive process that necessitates an inherent mechanism to flexibly fine-tune intracellular bioenergetics according to the translation status; however, such a molecular link remains lacking.

METHODS Slc25a26 knockout and cardiac-specific conditional knockout mouse models were generated to explore its function in vivo. Reconstructed adeno-associated virus was used to overexpress Slc25a26 in vivo. Cardiac hypertrophy was established by transaortic constriction (TAC) surgery. Neonatal rat ventricular myocytes were isolated and cultured to evaluate the role of SLC25A26 in cardiomyocyte growth and mitochondrial biology in vitro. RNA sequencing was conducted to explore the regulatory mechanism by SLC25A26. m¹A-modified tRNAs were profiled by RNA immuno-precipitation sequencing. Label-free proteomics was performed to profile the nascent peptides affected by S-adenosylmethionine (SAM).

RESULTS We show that cardiomyocytes are among the top cell types expressing the SAM transporter SLC25A26, which maintains low-level cytoplasmic SAM in the heart. SAM biosynthesis is activated during cardiac hypertrophy, and feedforwardly mobilizes the mitochondrial translocation of SLC25A26 to shuttle excessive SAM into mitochondria. Systemic deletion of Slc25a26 causes embryonic lethality. Cardiac-specific deletion of Slc25a26 causes spontaneous heart failure and exacerbates cardiac hypertrophy induced by transaortic constriction. SLC25A26 overexpression, both before or after TAC surgery, rescues the hypertrophic pathologies and protects from heart failure. Mechanistically, SLC25A26 maintains low-level cytoplasmic SAM to restrict tRNA m¹A modifications, particularly at A58 and A75, therefore decelerating translation initiation and modulating tRNA usage. Simultaneously, SLC25A26-mediated SAM accumulation in mitochondria maintains mitochondrial fitness for optimal energy production.

CONCLUSIONS These findings reveal a previously unrecognized role of SLC25A26-mediated SAM compartmentalization in synchronizing translation and bioenergetics. Targeting intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac hypertrophy and heart failure.

What Is New?

An activation of S-adenosylmethionine (SAM) biosynthesis during cardiac hypertrophy boosts a feed-forward mitochondrial translocation of its transporter SLC25A26 to shuttle excessive SAM into mitochondria.
SLC25A26-mediated cytoplasmic SAM containment restricts translation through inhibiting TRMT61A-mediated tRNA m¹A modifications, particularly at A58 and A75, which modulates translation initiation and codon usage.
SLC25A26-mediated mitochondrial SAM accumulation enhances mtDNA methylation and is required for the implement of mitochondrial fission and mitophagy, therefore maintaining optimal bioenergetics.
Cardiac-specific knockout of Slc25a26 causes spontaneous heart failure, and exacerbates transaortic constriction (TAC)-induced cardiac hypertrophy, while its overexpression rescues the hypertrophic pathologies.

What Are the Clinical Implications?

Cardiomyocyte-specific expression of SLC25A26 maintains low-level cytoplasmic SAM and contributes to the relatively low protein synthesis rate in the heart.
Targeting intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac hypertrophy and heart failure.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by grants from National Key R&D Program of China (2022YFA1104500 to LW and ZW), National Natural Science Foundation of China (82370392, 82070231 and 81722007 to ZW), CAMS Innovation Fund for Medical Sciences (2023-I2M-1-003 and 2022-I2M-2-001 to LW and ZW), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT320026 to LW and ZW), National High Level Hospital Clinical Research Funding (2022-GSP-GG-7 to LW and ZW), Shenzhen Medical Research Fund (B2302026 to ZW), Shenzhen Fundamental Research Program (ZDSYS20200923172000001 to ZW), and Science, Technology and Innovation Commission of Shenzhen Municipality (RCJC20210706091947009 to ZW; RCBS20221008093333076 to NG).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Collection and usage of human samples were approved by the Ethics Committee of the Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen [SP2023133(01)].

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

RNA-seq data have been deposited in NCBIs Gene Expression Omnibus (GEO) repository (accession: GSE254565 and GSE173737). Online microarray datasets are available from NCBIs GEO repository with corresponding accession codes as described in details in Supplemental Methods. Any additional information reported in this paper is available from the lead contact upon request.